Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Pan-tumor × S 1 (combination) × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 121 Pancreatic Neoplasms 34 Esophageal Neoplasms 17 Colorectal Neoplasms 16 Biliary Tract Neoplasms 15 Esophageal Squamous Cell Carcinoma 11 Neoplasm Metastasis 10 Carcinoma, Non-Small-Cell Lung 7 Gastrointestinal Neoplasms 6 Colonic Neoplasms 5 Cholangiocarcinoma 5 Adenocarcinoma 5 Neoplasms 4 Nasopharyngeal Carcinoma 4 Head and Neck Neoplasms 4 Advanced Pancreatic Cancer 4 Advanced Gastric Cancer 4 Recurrence 3 Rectal Neoplasms 3 Gastric Adenocarcinoma 3 Advanced Solid Tumors 3 NSCLC 2 Locally Advanced Pancreatic Cancer 2 Gastric Cancer Peritoneal Metastases 2 Gallbladder Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Bile Duct Neoplasms 2 mCRC 1

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co. Ltd

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡